Phase IIAndrogen Modulator
Compound 61507
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061507
Risk Class
MODERATE
Last Audit
Mar 14, 2108
Research Abstract
Androgen Modulator candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61507 is a androgen modulator asset inside androgen modulator innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase ii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061507 with updates logged 2108-03-14.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61507Androgen Modulator Program 61507
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061507
- [2] Operations Pulse • Androgen Modulator innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61507